Stay updated with breaking news from Agonist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar... | June 5, 2023
Redefining and Executing Dual Agonist Enterohormone Therapies for Obesity Sarah K. Browne, MD Vice President, Clinical Development ... | May 31, 2023
Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for OX40 agonist BGB-A445 and BCL-2 inhibitor... | May 25, 2023
New research presented at this year's European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study.
A new analysis of SURMOUNT-1, the first Phase 3 study of tirzepatide in adults for chronic weight management shows that tirzepatide improves body composition across a range of adult age groups.